Israeli biotech Nucleix has raised more than $5 million to finance its test for early detection of bladder cancer. Nucleix uses epigenetics (tiny changes in a cell’s DNA) to identify cancer cells. In the future, the product could also be used to test for colon, lung and prostate cancers.
http://www.globes.co.il/en/article-cancer-screening-co-nucleix-raises-5m-1000946774